Allergan announced that the Food and Drug Administration (FDA) has approved Juvederm Vollure XC for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults aged >21 years.
Juvederm Vollure XC utilizes the proprietary VYCROSS technology that blends different molecular weights of hyaluronic acid (HA), which add to the gel’s duration. The injectable gel is balanced with firmness and low cohesivity delivering results that last up to 18 months from the initial or touch-up injection.
Data from a clinical study showed 59% of patients had an improvement in moderate to severe nasolabial folds for up to 18 months. Also, 82% of patients reported they were very satisfied at 6 months and 68% of patients at 18 months. The most common adverse effects seen in the clinical study were temporary injection site responses such as swelling, tenderness, bruising, firmness lumps/bumps, redness, pain, discoloration, an ditching.
Juvederm Vollure XC will be available in April 2017.
For more information call (800) 433-8871 or visit Juvederm.com.